Ticker brief
UTHR UNITED THERAPEUTICS CORP
Consumer, Non-cyclical · Biotechnology
last close
$555.91
1 day
+1.6%
14 days
+3.6%
mkt cap
$23.6B
signals 14d
6
authors 14d
6
Sentiment — last 14 days
daily mean sentiment, 2026-06-29 → 2026-07-02 · now -0.08 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PrismMarketView | C | · | 1 | +0.35 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @BioStocks | C | -0.39 | 1 | -0.10 |
| @MartyChargin | C | -0.72 | 1 | -0.10 |
| @EmmanuelInvest | C | -1.12 | 1 | -0.05 |
| @BiopharmIQ | B | · | 1 | -0.05 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @BiopharmIQ | -0.05 | UTHR completed acquisition of Thymmune Tx with $140M upfront and up to $160M earn-outs. | — | tweet ↗ |
| 2026-07-02 | @EmmanuelInvest | -0.05 | United Therapeutics acquired Thymmune Therapeutics for cash and earn-outs. | — | tweet ↗ |
| 2026-07-02 | @MartyChargin | -0.10 | United Therapeutics acquired Thymmune for $140M upfront plus up to $160M milestones. | — | tweet ↗ |
| 2026-07-02 | @BioStocks | -0.10 | UTHR acquires Thymmune Therapeutics for $140M in cash. | — | tweet ↗ |
| 2026-06-30 | @OptionsFlowBoss | +0.35 | Reports a $370K call buyer. | +2.6% | tweet ↗ |
| 2026-06-29 | @PrismMarketView | +0.35 | United Therapeutics is expanding use of its FDA-approved lung perfusion platform. | +2.0% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.